ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eli Lilly, Celltrion and Samsung Bioepis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Eli Lilly×Celltrion×Samsung Bioepis×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eli LillyCelltrionSamsung Bioepis
studies on the registry2,2628433
open to participants now17342
phase 3 studies under way10451
reach primary completion within a year10461
programswith a study of their own in two years93+3 named only154

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEli LillyCelltrionSamsung Bioepis
Phase 1

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Celltrion: 6 of its 15 programs at phase 1

  1. ixekizumabphase 1
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. CT-P52phase 1
  5. CTL02phase 1

and 1 more — sign in to see them all

40%

Samsung Bioepis: 2 of its 4 programs at phase 1

  1. ixekizumabphase 1
  2. potassium L-ascorbatephase 1
50%
Phase 2

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
00%

Samsung Bioepis: 2 of its 4 programs at phase 2

  1. Ranibizumabphase 2
  2. afliberceptphase 2
50%
Phase 3

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%

Celltrion: 9 of its 15 programs at phase 3

  1. CT-P55phase 3
  2. CT-P51phase 3
  3. daratumumabphase 3
  4. empagliflozinphase 3
  5. CT-P43phase 3

and 4 more — sign in to see them all

60%
00%
Approved, new studies

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%
00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Celltrion3 readouts · 3 phase 3·

Celltrion, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinphase 3 · Dec 0 · NCT07093476
·

Celltrion, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CT-P51phase 3 · Feb 0 · NCT06939595

Celltrion, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. daratumumabphase 3 · Mar 8 · NCT06952478
·······
Samsung Bioepis1 readouts · 0 phase 3·······

Samsung Bioepis, Jun ’27: 1 program whose next study reaches primary completion

  1. ixekizumabphase 1 · Jun 9 · NCT07789964
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Celltrion

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Samsung Bioepis

New programs 1

  • afliberceptphase 2 · first study · Sep 21 · Macular Degeneration

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 16 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionEli LillyCelltrionSamsung Bioepis
Psoriasisall three · compare here

Eli Lilly in Psoriasis: 5 programs

  1. eltrekibartphase 2
  2. simepdekinraphase 2
  3. DC-806phase 2
  4. Tirzepatideapproved, new study
  5. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Psoriasis in search

Celltrion in Psoriasis: 3 programs

  1. CT-P55phase 3
  2. CT-P43phase 3
  3. ixekizumabphase 1

Their studies: Celltrion’s studies of Psoriasis in search

Samsung Bioepis in Psoriasis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Psoriasis in search

Arthritis, Rheumatoidall three · compare here

Eli Lilly in Arthritis, Rheumatoid: 4 programs

  1. clazakizumabphase 2
  2. sevoloprubartphase 2
  3. LY4213663phase 1
  4. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Arthritis, Rheumatoid in search

Celltrion in Arthritis, Rheumatoid: 2 programs

  1. CT-P13 SC Auto-Injectorphase 3
  2. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Rheumatoid in search

Samsung Bioepis in Arthritis, Rheumatoid: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Rheumatoid in search

Arthritis, Psoriaticall three · compare here

Eli Lilly in Arthritis, Psoriatic: 1 program

  1. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Arthritis, Psoriatic in search

Celltrion in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Arthritis, Psoriatic in search

Samsung Bioepis in Arthritis, Psoriatic: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Arthritis, Psoriatic in search

Diabetes Mellitus, Type 22 of 3 · compare here

Eli Lilly in Diabetes Mellitus, Type 2: 10 programs

  1. orforglipronphase 3
  2. retatrutidephase 3
  3. macupatidephase 2
  4. naperiglipronphase 2
  5. mazdutidephase 2

and 5 more — sign in to see them all

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 2 in search

Celltrion in Diabetes Mellitus, Type 2: 4 programs

  1. empagliflozinphase 3
  2. L03RD1phase 1
  3. L03RD2phase 1
  4. L03TD1phase 1

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 2 in search

–
Atherosclerosis2 of 3 · compare here

Eli Lilly in Atherosclerosis: 5 programs

  1. retatrutidephase 3
  2. lepodisiranphase 3
  3. muvalaplinphase 3
  4. VERVE-102phase 2
  5. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Atherosclerosis in search

Celltrion in Atherosclerosis: 1 program

  1. Ezetimibephase 3

Their studies: Celltrion’s studies of Atherosclerosis in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Eli Lilly in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. olomorasibphase 3
  2. Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408phase 1
  3. abemaciclibapproved, new study
  4. selpercatinibapproved, new study

Their studies: Eli Lilly’s studies of Carcinoma, Non-Small-Cell Lung in search

Celltrion in Carcinoma, Non-Small-Cell Lung: 1 program

  1. CT-P51phase 3

Their studies: Celltrion’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Diabetes Mellitus, Type 12 of 3 · compare here

Eli Lilly in Diabetes Mellitus, Type 1: 4 programs

  1. macupatidephase 2
  2. LY3938577phase 2
  3. LY4057996phase 1
  4. Tirzepatideapproved, new study

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 1 in search

Celltrion in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Diabetes Mellitus, Type 1 in search

–
Hypertension2 of 3 · compare here

Eli Lilly in Hypertension: 1 program

  1. orforglipronphase 3

Their studies: Eli Lilly’s studies of Hypertension in search

Celltrion in Hypertension: 3 programs

  1. rosuvastatinphase 3
  2. Amlodipinephase 3
  3. Ezetimibephase 3

Their studies: Celltrion’s studies of Hypertension in search

–
Axial Spondyloarthritis2 of 3 · compare here–

Celltrion in Axial Spondyloarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Celltrion’s studies of Axial Spondyloarthritis in search

Samsung Bioepis in Axial Spondyloarthritis: 1 program

  1. ixekizumabphase 1

Their studies: Samsung Bioepis’s studies of Axial Spondyloarthritis in search

Colorectal Neoplasms2 of 3 · compare here

Eli Lilly in Colorectal Neoplasms: 1 program

  1. olomorasibphase 3

Their studies: Eli Lilly’s studies of Colorectal Neoplasms in search

–

Samsung Bioepis in Colorectal Neoplasms: 1 program

  1. afliberceptphase 2

Their studies: Samsung Bioepis’s studies of Colorectal Neoplasms in search

Dyslipidemias2 of 3 · compare here

Eli Lilly in Dyslipidemias: 1 program

  1. solbinsiranphase 2

Their studies: Eli Lilly’s studies of Dyslipidemias in search

Celltrion in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Celltrion’s studies of Dyslipidemias in search

–
Heart Failure2 of 3 · compare here

Eli Lilly in Heart Failure: 1 program

  1. LY3971297phase 1

Their studies: Eli Lilly’s studies of Heart Failure in search

Celltrion in Heart Failure: 1 program

  1. empagliflozinphase 3

Their studies: Celltrion’s studies of Heart Failure in search

–

Show all 16

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetEli LillyCelltrionSamsung Bioepis
IL17Asimepdekinraixekizumabruleixekizumabrule
A target, or a pathogen for a vaccine, known for: Eli Lilly 50 of 93 · Celltrion 6 of 15 · Samsung Bioepis 3 of 4 programs (31 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).